Second-Generation HSP90 Inhibitor Onalespib Blocks mRNA Splicing of Androgen Receptor Variant 7 in Prostate Cancer Cells
Roberta Ferraldeschi(Royal Marsden NHS Foundation Trust), Johann S. de Bono(Royal Marsden NHS Foundation Trust), Tomoko Smyth, George Seed(Institute of Cancer Research), Jonathan Welti(Institute of Cancer Research), Wei Yuan(Shanghai Public Health Clinical Center), Mateus Crespo(Institute of Cancer Research), Nicola G. Wallis(Biota Pharmaceuticals (United States)), John F. Lyons, Marissa Powers(Institute of Cancer Research), Susana Miranda(Royal Marsden NHS Foundation Trust), Ruth Riisnaes(Institute of Cancer Research), Stephen R. Plymate(VA Puget Sound Health Care System), Somaieh Hedayat(Institute of Cancer Research), Daniel Nava Rodrigues(Institute of Cancer Research), Suzanne Carreira(Institute of Cancer Research), Hannah Wang(Institute of Cancer Research), Ines Figueiredo(Institute of Cancer Research), Gerhardt Attard(London Cancer), Swee Y. Sharp(Institute of Cancer Research), Paul Workman(Institute of Cancer Research)
Cited by 91
Related Papers
Integrative Clinical Genomics of Advanced Prostate Cancer
|Cell|2015|3.6k
Enzalutamide in Metastatic Prostate Cancer before Chemotherapy
|New England Journal of Medicine|2014|3k
Abiraterone in Metastatic Prostate Cancer without Previous Chemotherapy
|New England Journal of Medicine|2012|2.8k
DNA-Repair Defects and Olaparib in Metastatic Prostate Cancer
|New England Journal of Medicine|2015|2.2k
Trial Design and Objectives for Castration-Resistant Prostate Cancer: Updated Recommendations From the Prostate Cancer Clinical Trials Working Group 3
|Journal of Clinical Oncology|2016|1.6k